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ABSTRACT 
 
 There has been thorough documentation to support the role of dopamine in the control of 
prolactin production and secretion in various mammalian species, including the horse. However, 
there is evidence that other factors are involved in prolactin secretion. Seven experiments were 
conducted to assess factors that potentially might affect prolactin secretion in the horse. The first 
two experiments were conducted (separately) to test whether arginine vasopressin (AVP) or 
vasoactive intestinal polypeptide (VIP) affected prolactin secretion.  In each experiment, AVP or 
VIP was administered intravenously and blood samples were collected to determine the effect on 
prolactin secretion.  Neither peptide produced any alteration in plasma prolactin concentrations 
compared to simultaneous saline-injected controls (P > 0.1). Five subsequent experiments were 
conducted to assess the effects of various drugs on prolactin secretion in response to acute 
exercise. Pre-exercise treatments included dexamethasone (a glucocorticoid analog, administered 
15 h before exercise), naloxone (an opiod antagonist, administered 2 min before exercise), 
cabergoline (a dopaminergic agonist, administered 15 h before exercise), flunixin meglumine (a 
prostaglandin inhibitor, administered 15 min before exercise), and sulpiride (a dopamine 
antagonist that causes the release of prolactin, administered 1.5 h before exercise). In all 
experiments, exercise induced an immediate increase (P < 0.05) in plasma prolactin concentrations 
in control horses. Pretreatment with dexamethasone, naloxone, or flunixin meglumine did not alter 
(P > 0.1) plasma prolactin concentrations relative to saline-treated controls. Pretreatment with 
cabergoline completely obliterated (P < 0.01) the exercise induced rise in prolactin concentrations. 
Pretreatment with sulpiride caused an immediate increase (P < 0.001) in prolactin concentrations 
relative to controls, but resulted in no change in prolactin response to exercise 90 min later relative 
 vi
to controls. It is concluded that the only drug that had a significant effect on prolactin secretion was 
the dopaminergic agonist cabergoline. Direct administration of AVP or VIP, or perturbations of 
the adrenal cortical axis, the opioid system, or the prostaglandin system, had no effect on prolactin 
secretion as has been reported previously for other species. 
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INTRODUCTION 
 Prolactin is referred to as the “hormone of maternity” due to its regulation of mammary 
growth and development and its lactogenic properties (Hadley and Levine, 2007).  Other known 
functions in the body include hair growth, reproduction, and follicular activity (Hadley and 
Levine, 2007).  Lactotropes (prolactin secreting cells) are found in the pars distalis of the 
adenohypophysis and have been shown to be the prolactin secreting cells (Gregory et al., 2000).  
 A consistent rise in plasma prolactin concentrations has been shown to be detrimental in 
numerous animals.  Increased levels of prolactin (hyperprolactinemia) have been shown to cause 
infertility in human males and females (Serri et al., 2003).  In females, high prolactin levels can 
also cause galactorrhea (abnormal lactation), oligomenorrhea (infrequent menstruation) and even 
amenorrhea (absence of menstruation), while in men it causes hypogonadism, (little to no 
production of hormones in the sex glands; Serri et al., 2003).  Hyperprolactinemia can be caused 
by pathologies, such as a pituitary tumor, or diseases, such as hypothyroidism (Serri et al., 2003).   
 Dopamine has been shown to be a potent prolactin secretion inhibitor.  In the presence of 
dopamine, prolactin secretion is minimal, whereas when dopamine is absent, prolactin secretion 
rates are high (Moore, 1987).  It has been shown that prolactin has an auto-regulatory feedback 
onto tuberoinfundibular dopamine neurons (Moore, 1987).  Increased concentrations of prolactin 
due to a lack of stimulation of dopamine receptors located on lactotropes causes an auto-
regulatory feedback loop to the tuberoinfundibular dopamine neurons, which are then activated 
to produce more dopamine, resulting in reduced prolactin secretion (Moore, 1987).   
 The regulation of prolactin secretion in horses seems to be the same as the tonic 
dopaminergic inhibition described for most mammalian species. Pioneer work by Johnson and 
Becker (1987) showed that administration of the dopamine antagonist, sulpiride, stimulated 
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prolactin secretion in mares, and that administration of the dopaminergic agonist, bromocriptine, 
reduced resting prolactin concentrations. These effects of agonists and antagonists have been 
reported by many authors since then (Donadeu and Thompson, 2002; Colborn et al., 1991a; 
Redmond et al., 1994; Thomson et al., 1996). 
 In addition to the dopaminergic effects on prolactin secretion, several other neuropeptides 
and hormones have been implicated in the control of prolactin secretion in other species. 
Moreover, various factors, particularly exercise and other forms of sympathetic nervous system 
stimulation, have been shown to stimulate prolactin secretion in horses (Thompson et al., 1988; 
Rabb et al., 1989; Colborn et al., 1991b). What is not known is whether the exercise-induced 
prolactin response is due to an immediate reduction in dopamine input to the adenohypophysis, 
or whether some intermediate neurotransmitter, peptide, or hormone is released and directly 
affects the lactotropes.  
 The experiments described herein were conducted to assess potential intermediates in the 
control of prolactin secretion. The hormones tested, or the systems chosen for perturbation, were 
selected based on their known effects in other, usually smaller, species. The first two 
experiments were conducted to examine how two brain peptides, arginine vasopressin (AVP) 
and vasoactive intestinal polypeptide (VIP), affect resting prolactin levels in the horse.  These 
two peptides were chosen due to previous research showing stimulated prolactin secretion in 
various species after administration (Frawley and Neill, 1981; DePaolo et al., 1986).  
 Subsequent experiments were conducted to assess how perturbation of various systems 
(specifically the adrenal cortical, opioid, and prostaglandin systems) might alter the prolactin 
response to exercise. It was assumed that a significant perturbation of the response would 
indicate an involvement of that system in the normal prolactin response to exercise. 
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CHAPTER I 
REVIEW OF LITERATURE 
 
Pituitary Gland  
 
 The horse pituitary consists of two lobes: the adenohypophysis and the neurohypophysis 
(Ginther, 1992).  The adenohypophysis is also called the anterior lobe and it is primarily 
composed of glandular tissue (Hadley and Levine, 2007).  The adenohypophysis consists of the 
pars distalis and the pars tuberalis (Hadley and Levine, 2007).  The pars distalis has been shown 
to contain the cells that produce prolactin, the lactotropes (Gregory et al., 2000).  In a study done 
by Gregory et al. (2000), seasonally anestrous mares in November and sexually active mares in 
November had lactotropes that were only found in the pars distalis.  This was also detected in six 
of seven mares that were sexually active in July (Gregory et al., 2000).  The one mare that this 
did not pertain to had lactotropes in the pars distalis as well as in the pars tuberalis (Gregory et 
al., 2000).  In this one mare, there were more isolated lactotropes that were identified within the 
pars distalis compared to the pars tuberalis (Gregory et al., 2000).  This indicates that during the 
peak-breeding season some individuals may be able to express prolactin-secreting cells 
selectively within the pars tuberalis (Gregory et al., 2000).   
Prolactin 
 Prolactin has been referred to as the “hormone of maternity” for its regulation of 
mammary growth and development and for its lactogenic properties (Hadley and Levine, 2007).  
Prolactin is also known for many other functions, depending on species.  Stricker and Greuter 
(1929; summarized in Turner, 1977) reported that giving rabbits an extract of the anterior 
pituitary gland stimulates milk secretion. However, when mammary ducts were injected with 
anterior pituitary gland extract, only the alveoli attached to the treated ducts produced milk.  
These results showed that hormones in addition to prolactin act together with prolactin when 
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controlling mammary gland development. In addition to its involvement with mammary growth 
and development in mares (Redmond et al., 1994; Cross et al., 1995), prolactin has been reported 
to have other roles in the horse, including hair coat shedding in spring (Thompson et al., 1997) 
and induction of follicular activity and ovulation in seasonally anovulatory mares (Nequin et al., 
1993, Thompson et al., 1997; Kelley et al., 2006; Mitcham et al., 2010). In most mammals, 
prolactin is a single-chain protein made up of 197 to 199 amino acids (Hadley and Levine, 2007). 
In 1988, Lehrman et al. reported that equine prolactin had 199 amino acid residues and had a 
93% homology with porcine prolactin. 
Factors Affecting Prolactin Secretion in the Horse 
 Several factors have been identified that cause prolactin release from the pituitary, 
including season (Johnson, 1986), feeding behaviors (Nadal et al., 1997), exercise and other 
forms of stress (Colborn et al., 1991b; Sticker et al., 1995; Thompson et al., 1994), consumption 
of endophyte-infected tall fescue grass (Cross et al., 1995; McCann et al., 1992), dopaminergic 
antagonists (Moore, 1987), thyrotropin releasing hormone (TRH; Johnson, 1986), and 
prostaglandin-F2α (PGF2α; Thompson et al., 2013).  From various experiments, plasma prolactin 
concentrations in the horse have been shown to follow a cyclic pattern throughout the year.  That 
is, concentrations are high in the summer, start to decrease at the end of August, and reach their 
nadir in the months of November to February (Johnson, 1986; Fitzgerald et al., 2000).  It has 
been reported that seasonal changes in concentrations of prolactin are directly correlated to both 
photoperiod and temperature (Johnson, 1986).  This same study also noted that an increase of 
prolactin concentrations in the spring paralleled the loss of the winter hair coat, and decreasing 
concentrations of prolactin in the fall paralleled with the acquisition of the winter hair coat 
(Johnson, 1986).   
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 According to Depew et al. (1994) and Nadal et al. (1997), consumption of a meal results 
in an increase in prolactin concentrations approximately 4 to 6 h after onset of feeding. However, 
the prolactin increases after meal consumption did not vary when several types of feedstuffs 
were fed (pelleted, complete grain mixture; alfalfa cubes; or crushed corn; Nadal et al., 1997).   
Prolactin concentrations increase in horses that are stressed or exercised.  As little as 5 
minutes of exercise is enough to increase prolactin concentrations in stallions, geldings, and 
mares (Colborn et al., 1991b; Thompson et al., 1994).  An increase in prolactin concentrations 
can be seen in as quickly as 10 minutes after onset of exercise, and prolactin can continue to be 
elevated through 30 minutes (Colborn et al., 1991b).  Other forms of stress or physical activity 
also result in a surge in plasma prolactin concentrations, including twitching and mounting a 
mare, with or without ejacualtion (Thompson et al., 1988; Rabb et al., 1989).  
Pregnant mares that consume endophyte-infected tall fescue in the last three months of 
their pregnancy display a decrease in serum prolactin (Cross et al., 1995).  Along with the 
decrease in prolactin concentrations, they also display increased gestation lengths, agalactia, foal 
and mare mortality, tough and thickened placentas, weak and dysmature foals, increased 
sweating during warm weather, reduced progesterone concentrations, and an increase in serum 
estradiol-17β concentrations (Cross et al., 1995).  Antidopaminergic drugs have been shown to 
reverse the effects of endophyte-infected tall fescue ingestion (Cross et al., 1995).  Domperidone 
is a dopamine receptor antagonist that blocks both the normal dopaminergic input to the 
lactotropes as well as the ergot alkaloid that causes fescue toxicity. Domperidone is currently 
available commercially for treatment of pregnant mares grazing endophyte-infected tall fescue as 
Equidone(R), distributed by Dechra Veterinary Products in Overland Park, Kansas. 
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 Thyrotropin releasing hormone is a naturally occurring hypothalamic tripeptide that is the 
main regulator of thyroid stimulating hormone production and secretion (Hadley and Levine, 
2007). It has also been shown to cause a release of prolactin after intravenous injection in most 
species tested (Hadley and Levine, 2007).  Johnson (1986) was the first to show that TRH 
administration stimulated immediate prolactin secretion in horses. The prolactin response was 
dose-related between 50 and 500 μg of TRH (Johnson, 1986).  At lower doses (0.4, 2 or 10 μg of 
TRH), there was no difference between doses but there was still a significant increase in serum 
prolactin concentrations (Thompson et al., 1992).  Thyrotropin releasing hormone has been 
shown to act directly on lactotropes, acting through a specific TRH receptor, to stimulate 
prolactin (Hadley and Levine, 2007).  
 Prostaglandin-F2α has been shown to drastically increase the rate of prolactin synthesis in 
rat pituitary cells (Gautvik et al., 1976).  It is thought that PGF2α may inhibit the release of 
prolactin-inhibiting factor (dopamine) causing the increase in prolactin concentrations (Ojeda et 
al., 1979). The stimulatory effect of PGF2α on prolactin secretion has also been demonstrated in 
horses (Thompson et al., 2013). 
Other Factors Affecting Prolactin Secretion 
 Dexamethasone has been shown to decrease prolactin concentrations in the rat (Rossier et 
al., 1980).  Naloxone is an opioid antagonist, and binds to the opioid receptors normally found in 
the brain and prevents the binding of the endogenous opioid peptides (Rossier et al., 1980).  
Prolactin release is inhibited by endogenous opioids in horses (Aurich et al., 1996).  In a study 
done by Aurich et al. (1995), naloxone was shown to increase prolactin secretion in stallions in 
the months of May and August and almost significantly increase prolactin concentrations in 
December.  In contrast, naloxone has been shown to suppress prolactin secretion, and in the 
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presence of stress, naloxone partially suppressed the secretion of prolactin but did not abolish it, 
as did dexamethasone (Rossier et al., 1980).  A high dose of naloxone (10 mg/kg) caused a 
significant decrease in prolactin concentrations, both basal and stress-induced, whereas a lower 
dose of (0.2 mg/kg) did not (Rossier et al., 1980).    
AVP Effects on Prolactin  
  There is conflicting evidence in the literature concerning AVP and prolactin secretion. In 
a study done by DePaolo et al. (1986), administration of AVP into the third ventricle of the brain 
of rats suppressed prolactin secretion, which was hypothesized to be via a dopaminergic effect. 
However, Mai and Pan (1990) reported that intravenous administration of AVP stimulated 
prolactin secretion in ovariectomized, estrogenized female rats. A study by Funabashi et al. 
(1999) showed that administration of an AVP receptor antagonist caused a decrease in prolactin 
secretion in proestrous rats, which supports the hypothesis that prolactin increases in the 
presence of AVP. Also, Kjaer et al. (1991) reported that intravenous infusion of AVP stimulated 
prolactin secretion in rats in a dose dependent manner, and that administration of an antiserum 
against AVP, or an AVP antagonist, both inhibited the increase in prolactin secretion induced by 
the intracerebroventricular infusion of histamine. In healthy human males, Erfurth et al. (1996) 
found that intravenous AVP infusion caused consistent increases in plasma concentrations of 
prolactin and adrenocorticotropic hormone (ACTH). Moreover, Alexander et al. (1991) reported 
that exercise of racehorses produced an immediate increase in both ACTH and AVP in pituitary 
venous blood; AVP concentrations fell after exercise, whereas ACTH concentrations remained 
elevated for an extended period of time.  
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VIP Effects on Prolactin  
 A flurry of research in the late 1970's and early 1980's indicated that VIP was likely a 
physiologic releasing factor for prolactin in the rat (Kato et al., 1978; Samson et al., 1980; 
Enjalbert et al., 1980; Abe et al., 1985). However, this has not necessarily held true for other 
species (Falsetti et al., 1988; Mezey et al., 1985; Sawangjaroen et al., 1994).  One study showed 
that VIP may contribute to the regulation of prolactin from the anterior pituitary due to the fact 
that lactation causes an increase in VIP (Mezey et al., 1985).  It has been shown in rhesus 
monkey pituitary tissue that VIP will stimulate prolactin secretion in the absence and presence of 
dopamine (Frawley and Neill, 1981).  There is evidence in rat pituitary cells that prolactin 
secretion is regulated in an autocrine fashion by VIP produced in the hypothalamus (Nagy et al., 
1988).  In a study where VIP did not increase prolactin secretion, VIP was infused into the 
carotid artery of the ewe over a 10-minute period (Sawangjaroen et al., 1994).  While VIP is 
found within the external zone of the median eminence in sheep, there is a study that shows VIP 
is not found in the hypophyseal portal blood of the sheep like it is in other species (Sawangjaroen 
et al., 1997).    
Oxytocin and the Suckling Stimulus 
 Suckling has been shown to elicit an immediate release of pituitary prolactin (Benson et 
al., 1956; Fuchs et al., 1984; Grosvenor et al., 1986; Hadley and Levine, 2007).  Suckling also 
results in a rapid release of oxytocin from the neurohypophysis (Samson et al., 1986), which 
travels to the adenohypophysis causing prolactin to be released (Benson et al., 1956). It has also 
been shown that injections of oxytocin cause an increase in prolactin concentrations in the rat 
(Egil et al., 2006), by acting directly on the lactotropes. In contrast, Koprowski and Tucker 
(1971) reported that administration of oxytocin to lactating dairy cows did not alter serum 
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prolactin concentrations. In horses, Roser et al. (1989) reported that pregnant mares at term 
induced to deliver with oxytocin had higher plasma prolactin concentrations in the first stages of 
labor than mares that delivered spontaneously. However, there was no immediate prolactin 
response to the injected oxytocin. Similarly, administration of 100 units of oxytocin 
intramuscularly to stallions and geldings did not elicit a prolactin response (D. L. Thompson, Jr., 
unpublished data). 
Rationale for Present Experiments 
 The following experiments were designed to provide additional information on the 
mechanism(s) responsible for prolactin release in horses, particularly in response to stress and 
other forms of sympathetic nervous stimulation. The stress response in horses, epitomized by a 
brief exercise bout, includes immediate increases in plasma concentrations of prolactin 
(Thompson et al., 1988; Rabb et al., 1989; Colborn et al., 1991b), growth hormone (Thompson et 
al., 1994), adrenocorticotropin (Alexander et al., 1991; Nagata et al., 1999), cortisol (Thompson 
et al., 1988; Nagata et al., 1999), epinephrine (Thornton, 1985; Snow et al., 1992; Nagata et al., 
1999), and AVP (Alexander et al., 1991). In addition, other neuropeptides and hormones have 
been reported to be involved with prolactin secretion, both in the resting state and in response to 
various stressful stimuli. Thus, the first two experiments described herein tested whether two 
peptides, AVP and VIP, known to affect prolactin secretion in other species, would alter resting 
plasma prolactin concentrations in the horse. The subsequent experiments used the paradigm of 
exercise-induced prolactin secretion to test whether the adrenal cortical, opioid, or prostaglandin 
systems in the horse mediate prolactin release in response to stress. Note that one apparently 
obvious candidate, epinephrine, was not tested here, because recent research indicated that 
epinephrine administration does not stimulate prolactin secretion in geldings (Thompson et al., 
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2013). Oxytocin, another potential candidate, has also been tested previously in horses and found 
not to affect prolactin secretion (Roser et al., 1989; D. L. Thompson, Jr., unpublished data). 
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CHAPTER II 
RESPONSES TO POTENTIAL PROLACTIN SECRETAGOGUES IN HORSES: 
ARGININE VASOPRESSIN AND VASOACTIVE INTESTINAL POLYPEPTIDE 
 
Introduction 
 Although dopaminergic control of prolactin secretion has been well defined in various 
species, other brain peptides and hormones have been identified that cause an immediate 
prolactin release. Mai and Pan (1990) reported that intravenous administration of AVP 
stimulated prolactin secretion in ovariectomized, estrogenized female rats. A study by Funabashi 
et al. (1999) showed that administration of an AVP receptor antagonist caused a decrease in 
prolactin secretion in proestrous rats, which supports the hypothesis that prolactin increases in 
the presence of AVP. Also, Kjaer et al. (1991) reported that intravenous infusion of AVP 
stimulated prolactin secretion in rats in a dose dependent manner, and that administration of an 
antiserum against AVP, or an AVP antagonist, both inhibited the increase in prolactin secretion 
induced by the intracerebroventricular infusion of histamine. In healthy human males, Erfurth et 
al. (1996) found that intravenous AVP infusion caused consistent increases in plasma 
concentrations of prolactin and adrenocorticotropic hormone (ACTH). However, in a study 
reported by DePaolo et al. (1986), administration of AVP into the third ventricle of the brain of 
rats suppressed prolactin secretion. 
 Similarly, VIP has been shown to increase prolactin secretion in some species and have 
no effect on prolactin secretion in other species.  In rhesus monkeys, VIP stimulated prolactin 
secretion (Frawley and Neill, 1981).  Dopamine appears to have no effect on prolactin levels in 
VIP-treated rhesus monkeys (Frawley and Neill, 1981).  This shows that VIP is a compelling 
stimulator of prolactin secretion in rhesus monkeys that is able to override the dopamine control 
on prolactin (Frawley and Neill, 1981). Numerous studies have shown that VIP causes the 
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release of prolactin in rats (Kato et al., 1978; Samson et al., 1980; Enjalbert et al., 1980; Abe et 
al., 1985). However, this has not necessarily held true for other species (Falsetti et al., 1988; 
Mezey et al., 1985; Sawangjaroen et al., 1994). It has been reported that VIP antibodies or 
antagonists suppress prolactin secretion in rat pituitary cells (Nagy et al., 1988), indicating that 
VIP acts direectly on lactotropes to cause prolactin secretion in rats. 
 Due to the species variation in prolactin responses to AVP and VIP, it cannot be assumed 
that either would be a secretagogue for prolactin in horses. Given that stimulating prolactin has 
direct application in seasonally anovulatory mares (Kelley et al., 2006; Mitcham et al., 2010), the 
present experiments were conducted to determine whether AVP or VIP administration would 
stimulate prolactin release in horses.  
Materials and Methods 
Experiment 2.1. AVP administration to mares.   Eleven light horse mares between the 
ages of 6 and 21 yr, weighing between 385 and 615 kg, and with a body condition scores 
between 6 and 8 (Henneke et al., 1983), were used.  They were long term residents of the LSU 
AgCenter Horse Unit in Baton Rouge, Louisiana.  They were maintained on pasture consisting 
primarily of Alicia bermudagrass and winter ryegrass.  The experiment was conducted in mid-
May of 2012. 
 All mares were brought in from pasture the night before treatments and kept in a dry lot 
with water available on an ad libitum basis.  The following morning, the mares were quietly 
walked into an outdoor chute and tethered either in the chute or on the fence alongside the chute.  
At that time, each mare was fitted with an indwelling, 14-gauge catheter in the left jugular vein 
that was held in place with cyanoacrylate glue.  
13 
 
 The AVP (Sigma Chemical Co., St. Louis, MO) was dissolved in sterile 0.155 M saline 
such that all treatment injections were 5.0 mL.  Doses prepared were 0 (control), 0.05, 0.1 and 
0.2 mg in 5 mL.  Two initial blood samples were drawn from each mare at 10 min apart, and 
then treatment was administered through the jugular catheter. Three mares each received the 0, 
0.5, and 0.1 mg dose; two mares received the 0.2 mg dose.  Post-treatment blood samples were 
collected at 5, 10, 20, 30, 40, and 60 minutes relative to treatment injection.  All blood samples 
were immediately placed into sample tubes containing sodium heparin as an anticoagulant and 
were centrifuged at 1200 x g for 10 min.  Plasma was stored at –15°C until they were assayed for 
prolactin.  Prolactin was measured in all samples with a double-antibody radioimmunoassay 
previously validated for horse tissues (Colborn et al., 1991a). 
 Prolactin concentrations were analyzed by repeated measures analysis of variance 
(ANOVA) by the GLM procedure of SAS (SAS Instit., Cary, NC). The ANOVA tested the 
effect of treatment with the mare-within-treatment term, and tested the effect of time of sampling 
and its interaction with treatment with residual error. 
Experiment 2.2. VIP administration to geldings.  Twelve light horse geldings between 
the ages of 10 and 21 yr, weighing between 442 and 640 kg, and with body condition scores 
between 6 and 8, were used.  They were long term residents of the LSU AgCenter Horse Unit in 
Baton Rouge, Louisiana, and were housed and maintained in the same pastures as the mares in 
Experiment 2.1. The experiment was conducted in late May of 2012. 
 The geldings were prepared starting the night before as described for the mares in 
Experiment 2.1. On the day of treatment, the geldings were tethered alongside the fence and 
chute and jugular blood samples were collected at -10, 0, 10, 20, 30, 40, 60, 90, and 120 minutes 
relative to treatment injections.  In this case, blood was drawn via jugular venipuncture at each 
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time interval via 21-gauge needles attached to 7-mL evacuated blood tubes containing sodium 
heparin as the anticoagulant. Treatments were sterile saline (5 mL; controls, n = 6) and 0.25 (n = 
4) or 0.5 (n = 2) mg of VIP (Anaspec, Inc., Fremont, CA) dissolved in sterile saline (5 mL 
volume). Blood samples were handled, stored, and assayed for prolactin as described for 
Experiment 2.1. Statistical analysis of the prolactin concentrations was the same as described for 
Experiment 2.1. 
Results 
Experiment 2.1.  Mean prolactin concentrations for mares receiving 0, 0.25, and 0.5 mg 
of VIP are presented in Figure 2.1. There was no effect of AVP dose in the ANOVA (P = 0.99). 
There was an effect of time of sampling (P = 0.0007), but no interaction of dose and time of 
sampling (P = 0.39).  
Experiment 2.2.  Prolactin concentrations for geldings receiving 0, 0.25, or 0.5 mg of 
VIP are presented in Figure 2.2. Data for individual geldings at each dose are presented, as well 
as the means for each dose, to illustrate the variation among horses within the dose groups. 
Individual geldings had spurious, large increases in prolactin concentrations not typical of the 
groups. Although there was an effect of time of sampling (P = 0.0012) in the ANOVA, there was 
no effect of dose of VIP (P = 0.38) and no interaction with time of sampling (P = 0.49). 
Discussion 
 Administration of AVP or VIP at the doses used had no effect on prolactin secretion 
other than that seen in control horses, even though there were effects of time on prolactin 
concentrations in both experiments. Responses to known secretagogues of prolactin (e.g., 
sulpiride, TRH, or PGF2α; Johnson, 1986; Johnson and Becker, 1987; Thompson et al., 2013) in 
horses occur typically within 5 to 10 min of administration. The time effects of  
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Figure 2.1.  Mean plasma concentrations of prolactin in horses administered arginine 
vasopression (AVP) at time 0 at 0, 0.05, 0.1, or 0.2 mg in Experiment 2.1. There was an effect of 
time of sampling (P < 0.0007) in the ANOVA, but no effect (P > 0.1) of dose or interaction of 
dose and time. The pooled SEM was 3.5 ng/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2.  Plasma concentrations of prolactin in horses administered vasoactive intestinal 
polypeptide (VIP) at time 0 at 0, 0.25, or 0.5 mg in Experiment 2.2. There was an effect of time 
of sampling (P < 0.0012) in the ANOVA, but no effect (P > 0.1) of dose or interaction of dose 
and time. Data for the individual horses are shown to illustrate the variation in prolactin 
concentrations. The pooled SEM was 4.1 ng/mL.  
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prolactin concentrations observed in both experiments were unexpected; normally horses 
receiving 5 mL of saline intravenously have no immediate change in prolactin concentrations. 
However, spontaneous surges in prolactin concentrations have been reported (Roser et al., 1987; 
Thompson et al., 1992), and likely account for the variations in Experiment 2.2. Whether the 
time variations in Experiment 2.1, which seemed more coordinated, were physiologic, is 
unknown.  
 Route of administration of these two peptides has varied in previous experiments.  
DePaolo et al. (1986) administered AVP into the third ventricle of the brain of rats resulting in a 
suppression of prolactin secretion, which was hypothesized to be via a dopaminergic effect. 
However, most stimulatory effects of AVP on prolactin secretion have been after intravenous 
injection (Mai and Pan, 1990; Kjaer et al., 1991; Erfurth et al., 1996). Dose of peptide is another 
factor that must be considered, especially in the face of negative results on prolactin secretion. 
Synthetic AVP has a biological activity of approximately 600 IU/mg of peptide (Stedman's 
Medical Dictionary, 2006). A dose of AVP used in humans of 0.0143 IU/kg BW infused over a 
1.5-min period elevated plasma ACTH and cortisol concentrations within 15 min (Rye et al., 
1997). Based on that dose, the highest dose used in the present experiment (0.2 mg in a horse of 
approximately 500 kg, or 0.218 IU/kg BW) was approximately 15 times that dose used in 
humans. Doses of 0.05 to 0.4 IU/min administered to adult horses are recommended for 
increasing blood pressure in animals experiencing septic shock that do not respond to fluid 
replacement and norepinephrine therapy (Divers, 2008). It has been reported that 0.4 and 0.8 mg 
of AVP administered to normal horses of about 500 kg caused undesirable side-effects indicative 
of elevated blood pressure and peripheral vasoconstriction (D. L. Thompson, Jr., unpublished 
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data). Thus, it is unlikely that the lack of prolactin response in this experiment was due to 
insufficient dose of AVP. 
 There is no mention of effects of VIP in horses in the literature, thus the only possible 
comparison of dose is restricted to its administration in other species. Infusion of VIP into the 
uterine artery of sheep at 1 to 30 µg/min resulted in whole-body vasodilatation that was evident 
in both the infused and the contralateral sides of the uterine vasculature (Clark et al., 1982). In 
newborn sheep, VIP was a powerful pulmonary vasodilator with a threshold of 0.3 µg/kg BW 
(Kulik et al., 1984). Sawangjaroen and Curlewis (1994) infused VIP (1.8 nmol/min, or 6 µg/min) 
into the carotid artery of sheep over a 10 min period and observed an increase in heart rate to 
almost three-fold the resting value; in contrast, prolactin secretion was not affected. The highest 
dose of VIP administered in the present experiment was 0.5 mg, which would be approximately 
1 µg/kg BW for a horse of average body condition. Thus, this dose is similar to those causing 
significant biological effects in sheep. Unfortunately, possible effects of VIP on blood pressure 
were not monitored in the present experiment to confirm its biological activity at the doses 
administered. 
 In conclusion, these results of AVP and VIP administration to horses do not support the 
hypothesis that either peptide is involved with prolactin secretion in mares or geldings. Further 
study with higher doses of VIP may be warranted, but would unlikely result in responses 
different than those presented herein. 
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CHAPTER III 
EFFECT OF PRETREATMENT WTH DEXAMETHASONE, NALOXONE, 
CABERGOLINE, FLUNIXIN MEGLUMINE, OR SULPIRIDE ON THE PROLACTIN 
RESPONSE TO EXERCISE IN HORSES 
 
Introduction 
 It has been shown that various forms of stress in horses cause prolactin secretion to 
increase (Rabb et al., 1989; Colborn et al., 1991b; Thompson et al., 1994).  Plasma prolactin 
concentrations can continue to be increased as long as 30 min from acute exercise for 5 minutes 
in stallions (Colborn et al., 1991b).  The prolactin response to exercise can occur with as little as 
1 min of trotting in mares (D. L. Thompson, Jr., unpublished data). 
 The secretagogues of prolactin that are known to act via specific hormonal or 
neurotransmitter receptors on pituitary lactotropes are dopamine antagonists, which bind to 
dopamine receptors and block the inhibitory action of dopamine, and TRH, which binds to 
specific TRH receptors on the lactotropes and directly stimulates prolactin secretion (Hadley and 
Levine, 2007). When horses are stressed, it is not known how prolactin secretion is mediated. 
The two most commonly hypothesized models are 1) the stress causes an immediate reduction in 
dopaminergic input to the pituitary via the hypothalamic-pituitary portal system, and 2) the stress 
causes the release of an unknown stimulatory factor, such as TRH, that acts directly on the 
lactotropes. The following experiments were designed to test several drugs known to perturb the 
adrenal axis (dexamethasone), the opioid system (naloxone), the dopaminergic system 
(cabergoline), the prostaglandin synthetic pathway (flunixin meglumine), and possibly a short-
loop feedback system of prolactin on its own secretion (sulpiride). 
 Dexamethasone is a glucocorticoid analog that mimics the action of cortisol in the body. 
Cortisol is released as part of the sympathetic nervous system response to stress (Rabb et al., 
1989; Colborn et al., 1991b). Pretreatment with dexamethasone 1 day before exercise should 
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preclude ACTH from being secreted in response to exercise, due to its negative feedback on the 
hypothalamic-pituitary axis (Hadley and Levine, 2007). 
 It has also been proposed in the horse that opioid agonists inhibit the secretion of 
prolactin (Aurich et al., 1996).  Naloxone, which is an opioid antagonist, has been shown to 
increase prolactin secretion in stallions, in the absence of exercise or stress (Aurich et al., 1995).  
In contrast, naloxone has been shown to decrease prolactin secretion in the presence of stress in 
rats (Rossier et al., 1980).  The study done by Rossier et al. (1980) is contradictory to the study 
done by Aurich et al. (1996) unless there is an unknown relationship between naloxone and 
stress.  
 Given that dopamine is a known physiologic regulator of prolactin secretion (Hadley and 
Levine, 2007), the action of its analogs should be inhibitory to prolactin release after stress. In 
fact, Thomson et al. (1996) treated stallions with bromocriptine before sexual stimulation and 
seminal collection, and reported that it precluded the prolactin increase normally seen after 
collection (Rabb et al., 1989; Colborn et al., 1991b). Cabergoline is a powerful dopamine D2 
receptor agonist (Seeman, 2007) that can suppress prolactin secretion for at least 10 days in 
horses (Hebert, 2012).     
 Banamine is a trade name for flunixin meglumine, a non-steroidal anti-inflamatory drug 
that has been shown to inhibit prostaglandin synthesis in horses in general (Semrad et al., 1985) 
and PGF-2α production and secretion specifically in mares (Daels et al., 1991). Prostaglandin-
F2α administration has been reported to cause immediate prolactin release in horses (Thompson 
et al., 2013), and Ginther et al. (2012) reported that inhibition of PGF2α production with flunixin 
meglumine in mares resulted in a reduced prolactin secretion during the luteolytic phase. Similar 
results were reported for heifers by Pugliesi et al. (2012). Pretreatment with flunixin meglumine 
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before exercise should provide evidence as to whether PGF2α is involved with the prolactin 
response to that exercise. 
 Finally, sulpiride causes immediate prolactin release in horses due to its antagonism of 
dopamine receptors on the lactotropes. There have been reports that prolactin can act via short-
loop feedback, either at the hypothalamus or directly on the pituitary (autoregulation) to inhibit 
further prolactin release (Hadley and Levine, 2007). Thus, sulpiride pretreatment was assessed as 
a factor that might perturb exercise-induced prolactin release in the last experiment. 
Materials and Methods 
 General procedures.  Horses in the following experiments were long-term residents of 
the LSU AgCenter Horse Unit in Baton Rouge, Louisiana, and were routinely housed on pasture. 
For each exercise challenge, they were pretreated either the evening before exercise 
(dexamethasone, cabergoline) or the morning of exercise (naloxone, flunixin meglumine, and 
sulpiride). In all experiments, the horses were kept in a dry lot overnight and quietly walked into 
an outdoor chute in the morning. A halter was placed on each horse, which was then removed 
from the chute and tethered to the fence near the chute, or kept in the chute untethered.  
When all horses were in place, blood sampling for the first horse began. The order of 
horses was randomized, with the exception that treated and control horses were exercised 
alternately. Blood sampling in each case involved a pre-exercise sample followed by a sample at 
5, 10, and 20 min after the onset of exercise. Exercise was for 2 min in a round pen at a trot or 
canter; horses were encouraged by voice commands only. Blood was drawn by jugular 
venipuncture with 21-gauge needles into evacuated 7-mL tubes containing sodium heparin (143 
units). Blood samples were subsequently placed at 4°C and centrifuged at 1200 x g for 15 min; 
plasma was harvested and stored at -15°C. 
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Plasma concentrations of prolactin were determined by radioimmunoassay as described 
by Colborn et al. (1991a). Limit of sensitivity and intra- and interassay coefficients of variation 
averaged 0.2 ng/mL and 7 and 12%, respectively. 
Data from each experiment was analyzed by ANOVA that took into account the 
repetitive nature of the data (split-plot; Steel et al., 1997). Main effects of sex (where 
appropriate), treatment, and sampling time were assessed, as well as all two- and three-way 
interactions. Differences between treatment and control means for each time period were 
assessed by the least significant difference test (Steel et al., 1997). 
Experiment 3.1. Dexamethasone pretreatment.  Six light horse mares and six light 
horse geldings between the ages of 7 and 23 years, weighing between 410 and 615 kg, with body 
condition scores between 5 and 8 were used.  The experiment was conducted during June of 
2012.  Three mares and three geldings were administered dexamethasone (Sigma Chem. Co., St. 
Louis, MO; 40 µg/kg BW) in oil intramuscularly on the evening before the exercise challenge; 
three mares and three geldings received similar injections of oil and served as controls.   
Experiment 3.2. Naloxone pretreatment.  Six light horse mares and six light horse 
geldings between the ages of 14 and 21 years, weighing between 442 and 640 kg, with body 
condition scores between 6 and 8 were used. The experiment was conducted during June of 
2012.  Three mares and three geldings were administered naloxone (Sigma; 0.25 mg/kg BW) in 
saline intravenously 2 min before the exercise challenge; three mares and three geldings received 
similar injections of saline and served as controls. 
Experiment 3.3. Cabergoline pretreatment.  Six light horse mares and six light horse 
geldings between the ages of 7 and 23 years, weighing between 430 and 615 kg, with body 
condition scores between 6 and 8 were used.  The experiment was conducted during July of 
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2012.  Three mares and three geldings were administered cabergoline (1 mg) in long-acting 
vehicle intramuscularly the evening before the exercise challenge; three mares and three geldings 
received similar injections of saline and served as controls.  
Experiment 3.4. Flunixin meglumine pretreatment.  Ten light horse geldings between 
the ages of 7 and 20, weighing between 442 and 540 kg, with body condition scores between 6 
and 7 were used.    The experiment was conducted in October of 2012.  Five geldings were 
administered flunixin meglumine (Schering-Plough Animal Health, Kenilworth, NJ; 1.5 mg/kg 
BW) solution intravenously and five control geldings received a similar injection of saline. 
Blood samples were collected immediately before flunixin meglumine or saline injection, and 
then again 15 min later, which was immediately before exercise. Additional blood samples were 
collected at 5, 10, 15, 20 and 30 minutes after onset of exercise. 
Experiment 3.5. Sulpiride pretreatment.  Ten light horse geldings between the ages of 
7 and 21, weighing between 410 and 570 kg, with body condition scores between 5 and 7 were 
used. The experiment was conducted in October of 2012.  Five geldings were administered 
sulpiride (racemic mixture; Sigma; 0.01 mg/kg BW) in saline intravenously and five control 
geldings received a similar injection of saline. Blood samples were drawn immediately before 
injections and again at 5, 10, 20, 30, 60, and 89 minutes after injection.  Horses were then 
exercised starting at 90 min post-injection. Blood samples were collected at 5, 10, 15, 20 and 30 
minutes after onset of exercise. 
Due to the large prolactin response in sulpiride-treated geldings relative to the normal 
response to exercise, data from Experiment 3.5 were analyzed in two separate ANOVA: one with 
all data included, and one with only the 90-min samples and subsequent data included. This 
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allowed for better testing the effects of pretreatment with sulpiride (resulting in a large variation) 
on the exercise-induced prolactin concentrations (with smaller variations). 
Results 
Experiment 3.1.  There was an effect of time (P < 0.0001) in the ANOVA, reflecting the 
significant rise in prolactin concentrations after exercise in the two groups of horses (Figure 3.1).  
There was no effect (P > 0.1) of sex, dexamethasone treatment, or sex by treatment interaction, 
nor any interaction with time and the other factors in the analysis. 
Experiment 3.2.   There was an effect of time (P < 0.0001) in the ANOVA, again 
reflecting the significant rise in prolactin concentrations after exercise in the two groups of 
horses (Figure 3.2).  However, there was no effect (P > 0.1) of sex, naloxone treatment, or sex by 
treatment interaction, nor any interaction with time and the other factors in the analysis. 
Experiment 3.3.   There was an effect of time (P < 0.001) as well as a treatment by time 
interaction (P < 0.001) in the ANOVA, but no effect of sex or any interaction of other factors 
with sex (Figure 3.3). Control horses displayed the expected rise in prolactin concentrations after 
exercise, but horses treated with cabergoline had low and unchanging concentrations throughout 
the blood sampling period. Prolactin concentrations differed (P < 0.01) between groups for all 
time periods. 
Experiment 3.4.  There was an effect of time (P < 0.0001) in the ANOVA, reflecting the 
significant rise in prolactin concentrations after exercise in the two groups of horses (Figure 3.4). 
There was a trend (P = 0.074) towards higher prolactin concentrations in the treated group 
relative to controls; however, the difference was present from the first (pre-flunixin meglumine 
injection) sample and remained at a consistent level throughout the blood sampling period. There 
was no treatment by time interaction (P > 0.1). 
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Figure 3.1.  Mean plasma concentrations of prolactin in horses administered dexamethasone the 
evening before exercise for 2 min in Experiment 3.1. There was an effect of time of sampling (P 
< 0.0001) in the ANOVA, but no effect (P > 0.1) of treatment or interaction of treatment and 
time. The pooled SEM was 3.7 ng/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2.  Mean plasma concentrations of prolactin in horses administered naloxone 2 min 
before exercise for 2 min in Experiment 3.2. There was an effect of time of sampling (P < 
0.0001) in the ANOVA, but no effect (P > 0.1) of treatment or interaction of treatment and time. 
The pooled SEM was 2.2 ng/mL. 
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Figure 3.3.  Mean plasma concentrations of prolactin in horses administered cabergoline the 
evening before exercise for 2 min in Experiment 3.3. There was an interaction of treatment with 
time of sampling (P < 0.0001) in the ANOVA. Prolactin concentrations of control horses differed 
(P < 0.01) from those of treated horses for all time periods. The pooled SEM was 0.6 ng/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4.  Mean plasma concentrations of prolactin in geldings administered flunixin 
meglumine (Banamine) 15 min before exercise for 2 min in Experiment 3.4. There was an effect 
of time of sampling (P < 0.0001) in the ANOVA, and a trend (P = 0.074) for lower 
concentrations in control geldings. There was no interaction of treatment and time (P > 0.1). The 
pooled SEM was 0.7 ng/mL.  
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Experiment 3.5.   After sulpiride injection, prolactin concentrations increased (P < 
0.001) to a peak of >16 ng/mL in treated geldings and then gradually decreased to concentrations 
similar to controls by 89 min (Figure 3.5); concentrations in control geldings were relatively low 
and unchanged during the same time, as reflected by the treatment by time interaction (P < 
0.001) in the first ANOVA (all data). Analysis of the 90-min and subsequent data separately 
indicated no effect of treatment, time, or treatment by time interaction (P > 0.1). 
Discussion 
 Each treatment in the five experiments contained herein was designed to perturb a system 
in the body that could potentially be involved in prolactin secretion. With the known effects of 
hypothalamic dopamine input to the pituitary (Hadley and Levine, 2007), it was assumed that 
cabergoline treatment would likely abolish the prolactin response to exercise. However, if a 
prolactin releasing factor existed in horses as has been reported for other species (Watanobe  et 
al., 2000; Curlewis et al., 2002), it could possibly stimulate prolactin directly at the lactotrope 
and override the suppressive effects of the dopamine agonist. Given that no response was 
observed after exercise in horses receiving cabergoline, it is concluded that either the cabergoline 
suppression was too great, or that no alternate stimulatory factor is involved. 
 In general, the prolactin responses to exercise were consistently observed in control 
mares and geldings in all five experiments. These data also confirm that the magnitude of the 
prolactin response to exercise and other forms of stress is not as great as is observed after 
treatment with sulpiride (Clavier et al., 2012). As seen in Experiment 3.5, the prolactin response 
after sulpiride treatment was almost four times as great as that observed in control geldings after 
exercise. 
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Figure 3.5. Mean plasma concentrations of prolactin in control geldings and geldings 
administered sulpiride 90 min before exercise for 2 min in Experiment 3.5. Sulpiride stimulated 
(P < 0.0001) prolactin concentrations (top panel), but had no effect (P > 0.1) on the exercise-
induced prolactin response (bottom panel). Pooled SEM was 1.4 ng/mL for the sulpiride effect, 
and 1.1 ng/mL for the exercise effect. 
 
 
 Dexamethasone treatment was designed to feedback on the hypothalamic-pituitary axis to 
suppress corticotropin releasing hormone and ACTH secretion, which are known to respond to 
exercise in horses (Alexander et al., 1991). Blocking these two hormones should abolish, or 
diminish, the prolactin response to exercise, if in fact they were involved in that response. The 
very similar prolactin responses to exercise in the treated and control horses indicate that neither 
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of rats actually decreases prolactin secretion (Rossier et al., 1980), however no decrease was 
observed in the horses in this experiment. 
 Aurich et al. (1995a) reported that naloxone administration to stallions increased 
prolactin concentrations during May and August, and had a tendency to do so in December. 
Aurich et al. (1996) also reported that naloxone stimulated prolactin release in stallions, but not 
in luteal phase mares or geldings. In contrast, Aurich et al. (2002) reported no change in 
prolactin concentrations in stallions treated with naloxone. Aurich et al. (1995b) reported that 
prolactin secretion was induced by naloxone treatment in ovariectomized pony mares that had 
been pretreated with estradiol benzoate. However, Aurich et al. (1997) reported that prolactin 
release was significantly increased by naloxone administration in ovariectomized pony mares 
after mares had been pretreated with only melatonin, but not when they received a combination 
of estradiol benzoate and melatonin. Thus, the literature is contradictory on the effects of opioid 
antagonists on prolactin secretion in horses. The results of Experiment 3.2 indicate that naloxone 
treatment of mares and geldings had no direct effect on prolactin secretion in the first 15 min 
after administration, and subsequently no effect on the exercise-induced prolactin response. 
Flunixin meglumine is a potent inhibitor of prostaglandin synthesis in horses (Semrad et 
al., 1985) and has been used in doses similar to that used herein to abolish PGF2α production and 
release in mares (Daels et al., 1991; Ginther et al., 2012). Although intravenous administration of 
PGF2α was shown to stimulate prolactin secretion in mares (Thompson et al., 2013), flunixin 
meglumine administration at a dose used in previous studies had no effect on exercise-induced 
prolactin secretion in the geldings in Experiment 3.4. It is concluded that the prolactin response 
to exercise is likely not mediated by prostaglandin(s) in the horse.  
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 Sulpiride was first reported to increase prolactin concentrations in horses by Johnson and 
Becker (1987). Since then, multiple studies have shown the stimulatory effects of sulpiride on 
prolactin secretion in horses (Colborn et al., 1991a; Thomson et al., 1996; Donadeu and 
Thompson, 2002; Kelley et al., 2006). Stimulating prolactin secretion with sulpiride before 
exercise tested the possibility that a short-loop feedback, or perhaps an autoregulation, of 
prolactin secretion, is present in horses. This approach has the limitation that release of prolactin 
90 min before exercise may only deplete the releasable stores of prolactin rather than feeding 
back in a negative manner. Regardless, there was no significant effect of pretreatment with 
sulpiride on the exercise-induced release of prolactin 90 min later. A better approach to testing 
whether a negative short-loop or autoregulation of prolactin exists would be to inject prolactin 
exogenously. The main reason that approach has not been attempted is that no source of large 
amounts of equine prolactin are available, and use of a similar hormone, recombinant porcine 
prolactin, caused antibody production in pony mares (Thompson et al., 1997). 
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SUMMARY AND CONCLUSIONS 
 Seven experiments were conducted to investigate factors that affect pituitary prolactin 
secretion in the horse in the resting state and in response to exercise.  The first two experiments 
explored how two brain peptides affect resting prolactin levels.  The subsequent five experiments 
were conducted to examine the effects of perturbation of various systems within the body on the 
prolactin response to the stress of exercise. 
 In the first experiment, various doses of AVP (0, 0.05, 0.1 and 0.2 mg in 5 ml solution) in 
saline administered intravenously to determine their effect on prolactin secretion.  Although 
there was a time effect on prolactin concentrations, there was no alteration relative to the 0 dose 
response. It was concluded that AVP likely is not involved in prolactin secretion in a calm horse.   
 Various doses of VIP (0, 0.25 and 0.5 mg) were administered in the second experiment 
and it was determined that neither dose of VIP altered prolactin concentrations compared to the 0 
dose.  It was concluded that VIP also does not affect the lactotrope directly and is not a likely 
regulator of prolactin secretion in the horse.   
 The third experiment tested dexamethasone, a glucocorticoid agonist that feeds back 
negatively on corticotropin releasing hormone and ACTH, as a pretreatment to acute exercise.  
Prolactin responded to 2 min of exercise as expected, but pretreatment with dexamethasone did 
not perturb that response.   
 In the fourth experiment, the opioid antagonist naloxone was administered intravenously 
as a pre-exercise treatment. Naloxone had no effect on the prolactin response to exercise, thus 
endogenous opioid peptides are not likely involved with exercise-induced prolactin secretion in 
horses. 
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 Cabergoline, a long-acting dopamine agonist, was administered in the fifth experiment. 
The morning after administration, prolactin concentrations were suppressed and remained low 
throughout exercise and the post-exercise blood sampling period. Control horses displayed the 
normal exercise-induced prolactin response. It was determined that cabergoline abolished the 
prolactin response even in the presence of exercise. It was concluded that cabergoline is a potent 
inhibitor of prolactin secretion, and likely would override any stimulatory effect of exercise 
(such as a releasing hormone) even if it existed. 
 The sixth experiment was conducted using flunixin meglumine, a nonsteroidal anti-
inflammatory drug that prevents prostaglandin production and secretion, as a pretreatment to 
exercise. The exercise-induced prolactin response was not altered by flunixin meglumine 
treatment, indicating that prolactin response to exercise is unlikely mediated by prostaglandins.  
 The final experiment tested the effect of sulpiride treatment, which normally stimulates 
prolactin secretion directly at the lactotrope level by competing with dopamine for its receptors. 
As expected, pretreatment with sulpiride stimulated prolactin secretion, but it had no effect on 
the exercise-induced prolactin response 90 min later.  
It is concluded that the only drug that had a significant effect on prolactin secretion was 
the dopaminergic agonist cabergoline. Direct administration of AVP or VIP, or perturbations of 
the adrenal cortical axis, the opioid system, or the prostaglandin system, had no effect on 
prolactin secretion as has been reported previously for other species. 
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